Kurse werden geladen...
Prognose
Kaufen | 0 |
Halten | 1 |
Verkaufen | 0 |
Scoring-Modelle
Für dieses Unternehmen liegen uns bisher keine Scoring-Modelle vor.
News
Allarity Therapeutics Announces Appointment of Jeff Ervin as Chief Financial Officer
TARPON SPRINGS, Fla., July 7, 2025 -- Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib—a differentiated, dual PARP and WNT pathway inhibitor—as a personalized cancer treatment using its proprietary, drug-specific Drug Response Predictor (DRP®) patient selection technology, today announced the appointment of Jeff Ervin as the Company's new Chief Financial Officer (CFO).» Mehr auf globenewswire.com
Allarity Therapeutics Announces Dosing of Second Patient in New Phase 2 Trial of Stenoparib in Advanced Ovarian Cancer
TARPON SPRINGS, Fla., June 27, 2025 -- Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib—a differentiated, dual PARP and WNT pathway inhibitor today announced that the second patient has been dosed in its new Phase 2 clinical trial protocol evaluating stenoparib in patients with advanced, recurrent, platinum-resistant or platinum-ineligible ovarian cancer.» Mehr auf globenewswire.com
Allarity Therapeutics Announces Changes to Board of Directors
TARPON SPRINGS, Fla., June 11, 2025 -- Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib—a differentiated, dual PARP and WNT pathway inhibitor—as a personalized cancer treatment using its proprietary, drug-specific Drug Response Predictor (DRP®) patient selection technology—today announced that Jesper Høiland has been appointed to join the Company's Board of Directors. He will be replacing Joseph Vazzano, who will resign from the Board effective on June 30, 2025, following his valuable contributions to Allarity's development over the past two years.» Mehr auf globenewswire.com
Unternehmenszahlen
(EUR) | März 2025 | |
---|---|---|
Umsatz | 0,00 | - |
Bruttoeinkommen | 0,00 | 100,00% |
Nettoeinkommen | −2,53 Mio | 29,08% |
EBITDA | −2,81 Mio | 19,08% |
Fundamentaldaten
Metrik | Wert |
---|---|
Marktkapitalisierung | 13,50 Mio€ |
Anzahl Aktien | 15,08 Mio |
52 Wochen-Hoch/Tief | 6,34€ - 0,52€ |
Dividenden | Nein |
Beta | -0,15 |
KGV (PE Ratio) | −0,05 |
KGWV (PEG Ratio) | 0,00 |
KBV (PB Ratio) | 0,06 |
KUV (PS Ratio) | 0,00 |
Unternehmensprofil
Name | Allarity Therapeutics Aktie |
CEO | Thomas H. Jensen |
Mitarbeiter | 6 |
Assets entdecken
Shareholder von Allarity Therapeutics Aktie investieren auch in folgende Assets